SRP 4045

Drug Profile

SRP 4045

Alternative Names: SRP-4045

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Sarepta Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Dystrophin expression modulators; Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Duchenne muscular dystrophy

Most Recent Events

  • 28 Feb 2017 Sarepta Therapeutics has patent protection for SRP 4045 in USA (Sarepta Therapeutics Form 10-K, March 2017)
  • 01 Aug 2016 Phase-III clinical trials in Duchenne muscular dystrophy (In children, In adolescents) in USA (Parenteral) (NCT02500381)
  • 15 Oct 2015 Phase-I/II clinical trials in Duchenne muscular dystrophy (In adolescents, In adults, In children) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top